García-Chica, JesúsParaiso, West Kristian D.Zagmutt Caroxa, SebastiánFosch, AnnaReguera, Ana CristinaAlzina, SaraSánchez García, LauraFukushima, ShigetoToh, KazukoCasals, NúriaSerra i Cucurull, DolorsHerrero Rodríguez, LauraGarcía Gómez, JordiKataoka, KazunoriAriza Piquer, XavierQuader, SabinaRodríguez Rodríguez, Rosalía2023-03-292024-02-212023-02-212047-4830https://hdl.handle.net/2445/196203Targeting brain lipid metabolism is a promising strategy to regulate the energy balance and fight metabolic diseases such as obesity. The development of stable platforms for selective delivery of drugs, particularly to the hypothalamus, is a challenge but a possible solution for these metabolic diseases. Attenuating fatty acid oxidation in the hypothalamus via CPT1A inhibition leads to satiety, but this target is difficult to reach in vivo with the current drugs. We propose using an advanced crosslinked polymeric micelle-type nanomedicine that can stably load the CPT1A inhibitor C75-CoA for in vivo control of the energy balance. Central adminis- tration of the nanomedicine induced a rapid attenuation of food intake and body weight in mice via regu- lation of appetite-related neuropeptides and neuronal activation of specific hypothalamic regions driving changes in the liver and adipose tissue. This nanomedicine targeting brain lipid metabolism was successful in the modulation of food intake and peripheral metabolism in mice.13 p.application/pdfeng(c) Garcia Chica, Jesús et al., 2023MetabolismeMedicamentsMetabolismDrugsinfo:eu-repo/semantics/article7285902023-03-29info:eu-repo/semantics/openAccess